Johnson Johnson AbbVie: Paths to Pharma Dominance
Johnson & Johnson and AbbVie report divergent quarterly results, fueling a debate about two paths to pharma dominance...
Index funds distribute capital gains at occasional dates; knowing when helps you coordinate withdrawals and tax planning effectively.
25,550 articlesJohnson & Johnson and AbbVie report divergent quarterly results, fueling a debate about two paths to pharma dominance...
Investors are watching Nextdoor's 2025 earnings closely as the Q4 results shed light on monetization of local communi...
Quantum computing is moving from theory to real-world profit paths. This guide highlights two stocks and a practical ...
As 2026 unfolds, oil markets face three potential paths. This guide breaks down the scenarios and offers concrete ste...
Astronics reports a mixed Q1 2026 that tests the durability of its backlog and margin recovery. This article breaks d...
Glamsterdam targets a mid-2026 mainnet upgrade that aims to ease congestion and boost Ethereum’s throughput. Analysts...
Netflix faces a shifting market environment even as its ad-supported push gains momentum. This piece weighs the buy, ...
Bloom Energy has sprinted higher this year on an AI-powered energy story. As a late entrant, you’ll want a clear view...
Meta Platforms is gaining momentum in July 2026 as advertisers lean into AI-powered targeting. This piece explains wh...
No stock goes straight up, and Walmart’s latest report is a perfect example. Strong e-commerce gains meet a cautious ...
Palantir stock surging today has investors buzzing about what comes next. This article breaks down the catalysts, the...
The AI boom has turned Nvidia and AMD into poster children for opportunity—and risk. This guide breaks down the signa...